Kodiak Sciences Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter ended September 30, 2023; filed November 14, 2023. Kodiak is a clinical-stage biopharmaceutical company developing retinal-disease treatments and reported no product revenue.
Financial performance and position
Amounts below are in U.S. dollars; financial-statement amounts are converted from thousands to millions.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $36.2m | $61.7m | $159.7m | $211.6m |
| General and administrative expense | $18.3m | $17.8m | $54.3m | $55.7m |
| Total operating expenses | $54.5m | $79.5m | $213.9m | $267.3m |
| Net loss | $50.0m | $77.0m | $201.0m | $263.4m |
| Net loss per share | $0.95 | $1.47 | $3.84 | $5.04 |
| Operating cash used | Not provided for quarter | Not provided for quarter | $121.9m | $151.4m |
- At September 30, cash and cash equivalents were $345.7m, with restricted cash of $6.3m and no marketable securities. Current assets were $350.9m and current liabilities $70.8m.
- Total assets were $547.7m; stockholders’ equity was $302.4m and accumulated deficit $1,093.0m.
- Liabilities included a $100.0m liability related to the sale of future royalties and operating lease liabilities totaling $83.5m. The filing does not report conventional borrowings as a separate debt balance.
- For the first nine months, investing activities provided $277.0m, primarily from marketable-security maturities; financing activities provided $0.2m. Cash, cash equivalents and restricted cash increased $155.2m.
- No gross margin or profitability margin is meaningful because the company had no product revenue and remained loss-making.
Material changes and operating developments
- Q3 net loss narrowed by $27.0m year over year; nine-month net loss narrowed by $62.4m. Lower R&D spending was the primary operating-expense driver, partly offset in Q3 by higher G&A.
- R&D expense fell 41% in Q3 and 25% for the nine-month period. Management attributed the decrease mainly to winding down tarcocimab development, lower personnel-related stock compensation, and timing of manufacturing activity.
- In July 2023, Kodiak reported that the Phase 3 GLEAM and GLIMMER diabetic macular edema studies missed their primary non-inferiority endpoints. At the primary endpoint, average visual-acuity gains were 6.4 versus 10.3 letters in GLEAM and 7.4 versus 12.2 letters in GLIMMER for tarcocimab and aflibercept, respectively. The company reported a pooled cataract-event imbalance of 19% versus 9% and said cataracts may have contributed meaningfully to the efficacy failures.
- DAYLIGHT in wet AMD met its primary endpoint for monthly tarcocimab versus aflibercept every eight weeks; Kodiak reported no cataract imbalance in that study.
- BEACON in retinal vein occlusion reported one-year matched efficacy and greater durability versus aflibercept, including fewer injections. The filing also describes positive GLOW diabetic-retinopathy results announced November 6, after quarter-end: the study met its primary endpoint, with a reported 41.1% versus 1.4% achieving at least a two-step DRSS improvement. The filing’s wording for some GLOW secondary-endpoint event rates is internally unclear; verify against the underlying release or trial data.
- After the BEACON and GLOW results, Kodiak stated that it planned an additional pivotal study using a commercial tarcocimab formulation, with a potential strategy to support one BLA covering RVO, wet AMD and NPDR. This remains a plan, not an approval or assured outcome. KSI-501’s Phase 1 study had completed enrollment and dosing across dose levels; the company said it would explore both unconjugated and bioconjugate forms.
Liquidity, outlook, risks and unusual items
- Management believed cash and cash equivalents would fund anticipated operating and capital needs for at least 12 months after the November 14 filing date. Kodiak also expects continued operating losses and negative operating cash flows and says additional financing will be needed to complete development and any commercialization.
- No specific financial guidance, revenue forecast or quantified future expense outlook is provided. Management says funding needs depend on clinical progress, manufacturing, regulatory requirements and other factors; financing may not be available on acceptable terms.
- The dedicated Lonza Ursus manufacturing suite was commissioned as a cGMP facility in January 2023. Approximately $81.7m of related fixed assets were placed in service, of which $26.8m remained unpaid and recorded in accounts payable at quarter-end. Kodiak is considering strategic and operational alternatives for the facility as the tarcocimab program evolves.
- The Lonza agreement has an initial eight-year term, with extension rights; the filing describes potential manufacturing payments of approximately CHF150m over 2022–2030. Actual use and related costs may depend on pipeline plans and facility utilization.
- Key risks include clinical and regulatory uncertainty, tarcocimab’s mixed trial record and cataract findings, dependence on tarcocimab and KSI-501, competition, reliance on third-party manufacturing and suppliers, potential capital needs, and possible underutilization of Ursus. Management reported no material pending legal proceedings and effective disclosure controls as of September 30, 2023.
Most important facts for investors to verify
- Whether the planned additional tarcocimab pivotal study is agreed with regulators, adequately designed and funded, and whether the proposed single-BLA strategy is accepted by the FDA.
- The full GLOW secondary-endpoint results and the filing’s apparently inconsistent presentation of event rates; also assess the significance and cause of the cataract imbalance in GLEAM and GLIMMER.
- Updated cash runway and financing needs against the $121.9m nine-month operating cash outflow, future trial costs and the absence of product revenue.
- Ursus facility utilization, remaining commitments and potential costs or proceeds from alternatives, including the $26.8m unpaid fixed-asset balance and CHF-denominated obligations.
- Progress and safety findings for KSI-501, and the clinical, manufacturing and regulatory requirements for its alternative formulations.